Creating an Innovative AI-based Technology TCRact for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

118 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-06

Study Completion Date

2023-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The PROJECT OBJECTIVE is to create an innovative AI-based (Artificial Intelligence) IN SILICO TECHNOLOGY for the design and optimization of T-cell receptors (TCRs) capable of recognizing specific tumor antigens presented on Human Leukocyte Antigen (HLA). The technology will be based on bioinformatics (including molecular modelling) and artificial intelligence (including predictive, generative and optimization models). PROJECT TASKS are dedicated to the implementation of individual technological components (including the database necessary for their preparation) and to performing IN VITRO evaluation rounds to optimize the technology.

Integration, within an IN SILICO TECHNOLOGY, of processes which currently require huge amounts of in vitro laboratory experiments that are necessary for bringing new TCR-based cancer immunotherapies into clinical trials:

* finding appropriate TCRs targeting cancer neoantigen presented on a HLA molecule (pHLA)
* testing for potential TCR toxicity (targeting self antigens presented on healthy tissues)
* optimization of pHLA:TCR binding affinity and toxicity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

NCT04145232

Non Small Cell Lung Cancer Neoepitopes Neoantigens +3 more

UNKNOWN

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

NCT05292859

Gynecologic Cancer Colorectal Cancer Pancreatic Cancer +7 more

COMPLETED

Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy

NCT02931955

Allergy

COMPLETED

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

NCT00895323

Colorectal Cancer

UNKNOWN PHASE1

Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy

NCT03434912

CTC and Tumor Related Rare Cell

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Cancer Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COLON CANCER

This cohort will consist of 100 patients with Colon Cancer.

Collection of blood (PBMC), biopsy (FFPE) and stool samples.

Intervention Type OTHER

Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collection of blood (PBMC), biopsy (FFPE) and stool samples.

Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of advanced resectable colorectal cancer (Active stage II, III or IV)
* Histopathologically confirmed as adenocarcinoma
* Age 18 or over
* Being able to understand and sign the Informed Consent Form (ICF)
* Qualification for resection within 3 months from W0 or condition after primary tumor resection, not longer than 5 years from surgery

Exclusion Criteria

* Mucinous colorectal adenocarcinoma
* Canal and anal edge cancer,
* Adenocarcinoma of the appendix,
* Patients treated with neoadjuvant therapy or radiation therapy in the 3 months prior to study enrollment.
* Patients treated with systemic chemotherapy in the 3 months prior to study enrollment.
* Histopathological diagnosis other than adenocarcinoma
* Remission
* History of inflammatory bowel diseases
* Pregnancy
* HIV infection
* Active infection with hepatitis B and C viruses
* Leukocytopenia

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No